Artelo Biosciences Inc (ARTL)

$1.86 -0.48 (-20.51%)
Market Cap 2.17M
Revenue (ttm) 0.00
Net Income (ttm) -12.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 189,362
Avg Vol 4,250,002
Day's Range N/A - N/A
Shares Out 938,000.00
Stochastic %K 3%
Beta 0.05
Analysts Hold
Price Target $18.00

Company Profile

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 925 7049
Address:
505 Lomas Santa Fe, Suite 160, Solana Beach, United States
modrica3
modrica3 May. 15 at 3:43 PM
$ARTL well dilution is not a joke it basically kills every stock
0 · Reply
Ohadiz
Ohadiz May. 15 at 3:18 PM
$ARTL Wow
0 · Reply
johanroskam61
johanroskam61 May. 15 at 1:47 PM
1 · Reply
NYSE_TRADERS
NYSE_TRADERS May. 15 at 11:00 AM
$ARTL wow . This garbage continue to impress me . Go down bellow 1$ MF
0 · Reply
johanroskam61
johanroskam61 May. 15 at 9:21 AM
1 · Reply
STLHD
STLHD May. 14 at 9:06 PM
$ARTL for any idiotic bag holders like me....Widened Q1 net loss of $3 mil with no revenue. Improved balance sheet to $10.3 mil to support upcoming clinical milestones. Regained Nasdaq compliance, advanced ART27.13 and 12.11 trials. Positive interim data for cancer cachexia. Shifting focus toward advancing its lead analgesics platform to a Phase 2 study and seeking partners for cancer-related anorexia program. https://finance.yahoo.com/sectors/healthcare/articles/artelo-biosciences-provides-business-outlining-200500295.html Bullish only because it's at it's 1 year low and I sucked some Hopium
2 · Reply
simplifocused
simplifocused May. 14 at 1:19 PM
$ARTL Information only, NFA
0 · Reply
FeliciaMath
FeliciaMath May. 14 at 12:05 AM
$ARTL what a loser
0 · Reply
NYSE_TRADERS
NYSE_TRADERS May. 13 at 5:35 PM
$ARTL waiting this garbage to drop bellow 2 $
0 · Reply
STLHD
STLHD May. 12 at 2:37 PM
$ARTL 5/19 Q1 earnings with conf call 5/20 6:30 AM PT (per AI).
1 · Reply
Latest News on ARTL
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results

May 14, 2026, 4:05 PM EDT - 23 hours ago

Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results

Artelo Biosciences files $75M mixed securities shelf

2026-05-04T20:48:41.000Z - 10 days ago

Artelo Biosciences files $75M mixed securities shelf

Artelo Biosciences announces collaboration with ScienceMachine

2026-04-28T13:43:29.000Z - 17 days ago

Artelo Biosciences announces collaboration with ScienceMachine

Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development

Apr 28, 2026, 8:25 AM EDT - 17 days ago

Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development

AI

Artelo Biosciences announces publication of article on ART26.12

2026-04-20T12:15:49.000Z - 25 days ago

Artelo Biosciences announces publication of article on ART26.12

Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile

Apr 20, 2026, 7:50 AM EDT - 25 days ago

Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile

Artelo Biosciences files to sell 9.82M shares of common stock for holders

2026-04-07T20:25:22.000Z - 5 weeks ago

Artelo Biosciences files to sell 9.82M shares of common stock for holders

Artelo Biosciences regains compliance with Nasdaq

2026-04-07T13:09:13.000Z - 5 weeks ago

Artelo Biosciences regains compliance with Nasdaq

Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements

Apr 7, 2026, 7:50 AM EDT - 5 weeks ago

Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements

Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 30, 2026, 4:46 PM EDT - 6 weeks ago

Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Artelo Biosciences Soars 230% on Obesity Push — Why Is ARTL Stock Now Crashing?

2026-03-30T09:39:29.000Z - 6 weeks ago

Artelo Biosciences Soars 230% on Obesity Push — Why Is ARTL Stock Now Crashing?

LLY NVO

Artelo Biosciences announces $11M private placement priced at-the-market

2026-03-27T14:45:29.000Z - 7 weeks ago

Artelo Biosciences announces $11M private placement priced at-the-market

Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 27, 2026, 10:40 AM EDT - 7 weeks ago

Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Artelo announces expansion opportunity for ART27.13 in muscle preservation

2026-03-25T20:40:32.000Z - 7 weeks ago

Artelo announces expansion opportunity for ART27.13 in muscle preservation

Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments

Mar 25, 2026, 4:05 PM EDT - 7 weeks ago

Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments

Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength

Mar 25, 2026, 7:31 AM EDT - 7 weeks ago

Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength

Artelo Biosciences files to sell 4.27M shares of common stock for holders

2026-03-24T21:35:16.000Z - 7 weeks ago

Artelo Biosciences files to sell 4.27M shares of common stock for holders

Artelo Biosciences files to sell 1.64M shares of common stock

2026-03-20T21:20:34.000Z - 7 weeks ago

Artelo Biosciences files to sell 1.64M shares of common stock

Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum

Mar 18, 2026, 10:41 AM EDT - 2 months ago

Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum

YYGH

Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study

Mar 18, 2026, 8:07 AM EDT - 2 months ago

Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study

Artelo announces third-party fully funded clinical study agreement for ART27.13

2026-03-18T11:45:26.000Z - 2 months ago

Artelo announces third-party fully funded clinical study agreement for ART27.13

Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients

Mar 18, 2026, 7:41 AM EDT - 2 months ago

Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients

Artelo Biosciences Inc trading halted, news pending

2026-03-09T23:50:10.000Z - 2 months ago

Artelo Biosciences Inc trading halted, news pending

Artelo Biosciences announces 3-for-1 reverse stock split

2026-03-06T13:13:39.000Z - 2 months ago

Artelo Biosciences announces 3-for-1 reverse stock split

Artelo Biosciences Announces Reverse Stock Split

Mar 6, 2026, 8:00 AM EST - 2 months ago

Artelo Biosciences Announces Reverse Stock Split

Artelo Biosciences reports FY25 EPS ($12.52)

2026-02-24T13:05:52.000Z - 2 months ago

Artelo Biosciences reports FY25 EPS ($12.52)

Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results

Feb 24, 2026, 8:00 AM EST - 2 months ago

Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results

Artelo Biosciences Transcript: AGM 2026

Jan 30, 2026, 11:00 AM EST - 3 months ago

Artelo Biosciences Transcript: AGM 2026

Artelo comments on White House Executive Order expanding CBD research

2025-12-23T14:05:26.000Z - 5 months ago

Artelo comments on White House Executive Order expanding CBD research

Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate

Dec 23, 2025, 9:00 AM EST - 5 months ago

Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate

Artelo Biosciences announces publication of research on SBFI103

2025-12-03T13:35:39.000Z - 5 months ago

Artelo Biosciences announces publication of research on SBFI103

Artelo Biosciences downgraded to Hold from Buy at Maxim

2025-11-19T12:55:09.000Z - 6 months ago

Artelo Biosciences downgraded to Hold from Buy at Maxim

Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 8:00 AM EST - 6 months ago

Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results

Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer

Nov 4, 2025, 8:30 AM EST - 6 months ago

Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer

Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer

Oct 27, 2025, 8:00 AM EDT - 7 months ago

Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer

Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit

Oct 15, 2025, 9:15 AM EDT - 7 months ago

Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit

Artelo Biosciences Announces Closing of $2.0 Million Public Offering

Oct 1, 2025, 4:05 PM EDT - 8 months ago

Artelo Biosciences Announces Closing of $2.0 Million Public Offering

Artelo Biosciences Announces Pricing of $2.0 Million Public Offering

Sep 30, 2025, 8:30 AM EDT - 8 months ago

Artelo Biosciences Announces Pricing of $2.0 Million Public Offering

Artelo Biosciences Announces Proposed Underwritten Public Offering

Sep 29, 2025, 7:15 PM EDT - 8 months ago

Artelo Biosciences Announces Proposed Underwritten Public Offering

Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference

Sep 29, 2025, 8:30 AM EDT - 8 months ago

Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference

Artelo Biosciences Announces Closing of $3.0 Million Public Offering

Sep 5, 2025, 4:05 PM EDT - 8 months ago

Artelo Biosciences Announces Closing of $3.0 Million Public Offering

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

Sep 4, 2025, 8:37 AM EDT - 9 months ago

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

Sep 3, 2025, 11:33 AM EDT - 9 months ago

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

Sep 3, 2025, 8:45 AM EDT - 9 months ago

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Aug 25, 2025, 7:55 AM EDT - 9 months ago

Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 8:00 AM EDT - 9 months ago

Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results

Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13

Aug 11, 2025, 9:15 AM EDT - 9 months ago

Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13

Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset

Aug 4, 2025, 7:30 AM EDT - 10 months ago

Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset

Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression

Aug 1, 2025, 7:45 AM EDT - 10 months ago

Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression

Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium

Jul 9, 2025, 7:50 AM EDT - 11 months ago

Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium

Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model

Jul 7, 2025, 7:45 AM EDT - 11 months ago

Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Jun 30, 2025, 7:45 AM EDT - 11 months ago

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing

Jun 26, 2025, 8:00 AM EDT - 11 months ago

Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing

Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

Jun 5, 2025, 9:00 AM EDT - 1 year ago

Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression

Jun 2, 2025, 9:00 AM EDT - 1 year ago

New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025, 8:00 AM EDT - 1 year ago

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis

Apr 28, 2025, 8:45 AM EDT - 1 year ago

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis

Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

Mar 31, 2025, 8:30 AM EDT - 1 year ago

Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

Mar 3, 2025, 8:00 AM EST - 1 year ago

Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®

Feb 14, 2025, 9:00 AM EST - 1 year ago

Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®

Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland

Feb 11, 2025, 9:00 AM EST - 1 year ago

Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

Jan 13, 2025, 9:00 AM EST - 1 year ago

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia

Dec 9, 2024, 9:15 AM EST - 1 year ago

Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia

Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit

Nov 18, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit

Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium

Nov 13, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium

Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's “Preclinical Screening Platform for Pain” Program

Nov 5, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's “Preclinical Screening Platform for Pain” Program

Artelo Biosciences Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 16, 2024, 4:00 PM EDT - 1 year ago

Artelo Biosciences Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th

Oct 9, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th

Artelo Biosciences Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Artelo Biosciences Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

modrica3
modrica3 May. 15 at 3:43 PM
$ARTL well dilution is not a joke it basically kills every stock
0 · Reply
Ohadiz
Ohadiz May. 15 at 3:18 PM
$ARTL Wow
0 · Reply
johanroskam61
johanroskam61 May. 15 at 1:47 PM
1 · Reply
NYSE_TRADERS
NYSE_TRADERS May. 15 at 11:00 AM
$ARTL wow . This garbage continue to impress me . Go down bellow 1$ MF
0 · Reply
johanroskam61
johanroskam61 May. 15 at 9:21 AM
1 · Reply
STLHD
STLHD May. 14 at 9:06 PM
$ARTL for any idiotic bag holders like me....Widened Q1 net loss of $3 mil with no revenue. Improved balance sheet to $10.3 mil to support upcoming clinical milestones. Regained Nasdaq compliance, advanced ART27.13 and 12.11 trials. Positive interim data for cancer cachexia. Shifting focus toward advancing its lead analgesics platform to a Phase 2 study and seeking partners for cancer-related anorexia program. https://finance.yahoo.com/sectors/healthcare/articles/artelo-biosciences-provides-business-outlining-200500295.html Bullish only because it's at it's 1 year low and I sucked some Hopium
2 · Reply
simplifocused
simplifocused May. 14 at 1:19 PM
$ARTL Information only, NFA
0 · Reply
FeliciaMath
FeliciaMath May. 14 at 12:05 AM
$ARTL what a loser
0 · Reply
NYSE_TRADERS
NYSE_TRADERS May. 13 at 5:35 PM
$ARTL waiting this garbage to drop bellow 2 $
0 · Reply
STLHD
STLHD May. 12 at 2:37 PM
$ARTL 5/19 Q1 earnings with conf call 5/20 6:30 AM PT (per AI).
1 · Reply
NYSE_TRADERS
NYSE_TRADERS May. 12 at 2:00 PM
$ARTL This stock have no value ..bellow 1$ again...
0 · Reply
NYSE_TRADERS
NYSE_TRADERS May. 12 at 1:59 PM
$ARTL This thing have no value my friend. See you bellow 1 $
0 · Reply
Jsnipes401
Jsnipes401 May. 12 at 12:39 PM
$ARTL this thing is about to slingshot like crazy
0 · Reply
NYSE_TRADERS
NYSE_TRADERS May. 12 at 11:23 AM
$ARTL One direction …. Down !
0 · Reply
NYSE_TRADERS
NYSE_TRADERS May. 12 at 8:58 AM
$ARTL Garbage !
0 · Reply
NYSE_TRADERS
NYSE_TRADERS May. 11 at 8:33 PM
$ARTL aRTL is a buy at 1$
0 · Reply
NYSE_TRADERS
NYSE_TRADERS May. 11 at 7:14 PM
$ARTL This garbage have not value at all . They will drop the price to 1.80$ . Not bellow 1 $ because delisting will happen ! Fraud
0 · Reply
Adubstradesmini
Adubstradesmini May. 11 at 12:32 PM
$ARTL shorts gonna cover at all time lows to manage risk will send us up to 3-4$
0 · Reply
Adubstradesmini
Adubstradesmini May. 11 at 12:17 PM
$ARTL $MRNA
0 · Reply
Adubstradesmini
Adubstradesmini May. 11 at 12:17 PM
$ARTL grabbing some here at all time lows RSI verifies it’s oversold
1 · Reply
MHBTwister
MHBTwister May. 9 at 12:13 AM
$ARTL $THERE is a lack of interest because the volume is too low and traders are seeking volume to flatten price and i dicate a reversal and bottom. Overall sentiment is bearish, just need a Game stop play here to rocket the stock price off.
0 · Reply
FeliciaMath
FeliciaMath May. 8 at 9:20 PM
$ARTL made new 2 month low today. knew it. watching
0 · Reply